Calprotectin May Predict Arthritis Relapse
Baseline calprotectin serum levels independently predicted disease relapse in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) taking tumor necrosis factor inhibitors (TNFi) therapy, according to a study published online Dec. 13, 2018 in Arthritis Research & Therapy. Predicting relapses could improve care and avoid related costs, the authors say. Calprotectin, a proinflammatory factor, is a known biomarker of disease activity and predicts relapse in juvenile idiopathic arthritis. The present study analyzed the accuracy of serum calprotectin levels and drug trough serum levels (TSL) to detect subclinical disease activity and predict relapse in RA and PsA patients. Enrolled patients were in remission or had low disease activity while receiving TNFi (March 2013 to September 2014). While 103 patients (47 RA, 56 PsA) enrolled at a single center, only 95 completed one year of follow-up. Calprotectin serum levels, TNFi trough serum levels, and antidrug antibodies were evaluated at baseline and during disease relapse using an enzyme-linked immunosorbent assay test kit. Additionally, serum samples were collected at 4, 8, and 12 months of follow-up to assess longitudinal changes in drug trough serum levels. Over the year of follow-up, 12 patients experienced a relapse. While time-to-remission/low disease activity, calprotectin levels and TNFi TSL […]
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article